Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mythbluster, I said that 40% of the blame for the share price goes to management and 60% goes to posters such as yourself. Once again, reading comprehension is not your strong suit.
Here you go Jerseyboy. The company should release a follow-up PR about share structure and answer if the preferreds have been converted to commons and if not why not. They claimed they were going to convert the 12 million preferreds to commons using a 1:1 ratio which would give SIVC 28 million shares outstanding. This PR is from Feb 12.
ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR
On January 26, 2007, the Board of Directors of S3 Investment Company, Inc. (the “Company”) approved to amend the Company’s Articles of Incorporation to effect a one-for-one hundred fifty reverse stock split of all outstanding and authorized shares of common stock. The authorized capital stock now consists of 66,000,000 shares of common stock, $.001 par value, and 100,000,000 shares of preferred stock, $.001 par value. Following the reverse split, the number of shares of common stock outstanding decreased from 2.4 billion shares to 16 million shares.
The Reverse Split will affect all of the holders of the Company's Common Stock uniformly, except for insignificant changes that will result from the rounding up of fractional shares. The reverse split will affect neither Series B Preferred nor Series C Preferred stock. The Series B Preferred stock is convertible into common stock on a one-for-one basis. There are currently 12 million shares of Series B Preferred stock issued and outstanding, and it is management's intention to have all Series B Preferred stock converted into common stock immediately after the reverse split has been effected. The one million shares of Series C Preferred stock issued to Chairman and CEO James Bickel as security on a personal guarantee he provided for financing are expected to be cancelled once the debt to La Jolla Cove Investors has been repaid.
The Company filed the Amendment to the Articles of Incorporation effecting the one-for-one hundred fifty reverse stock split with the Secretary of State of the State of California on February 7, 2007, a copy of which is attached as Exhibit 3.2. The amendment became effective at 8:00 a.m. Eastern Time, on February 12, 2007. The Company’s common stock began trading on a post-split basis on February 12, 2007 on the Pink Sheets under the ticker symbol "SIVC”.
http://freerealtime.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4944466&Type=HTML
Well I dont retract that comment at all. As I have said on countless occasions, I like the business model but am not happy with management. Obviously reading comprehension isnt your strong suit.
S3 Investment Company Announces Chairman CEO Visit to Subsidiaries Operating in China
Wednesday April 18, 9:51 am ET
Meetings With Additional Potential Reverse Merger Clients May Yield New Contracts
DANVILLE, CA--(MARKET WIRE)--Apr 18, 2007 -- S3 Investment Company, Inc. (Other OTC:SIVC.PK - News), a holding company with two subsidiaries doing business in the China market, today announced that chairman and chief executive officer Jim Bickel has traveled to China to visit the company's subsidiary operations, SINO UJE, Ltd. and Redwood Capital, Inc.
The trip includes oversight of SINO UJE's presence at the China International Medical Equipment Fair Spring 2007 Conference, which is being held this week in Dalian, China. Mr. Bickel is also expected to meet with the Redwood Capital's current reverse merger clients, including the recently signed Shandong Green Paper Co. Ltd.
Mr. Bickel's trip began when he arrived in Beijing and met with Charlie Wu, the managing director of Redwood Capital, at the company's registered offices. Redwood Capital management reviewed with Mr. Bickel the progress with existing clients and planned to finalize agreements with prospective clients that are most ready for initial contract stage.
After traveling to briefly attend an East/West Investment Forum, Mr. Bickel arrived in Dalian, where SINO UJE exhibited at the China International Medical Equipment Fair Spring 2007 Conference. Mr. Bickel met with SINO UJE management, including managing director Li Jun at the event.
From Dalian, Mr. Bickel traveled to Hong Kong to meet with Chief Capital, which works with Redwood Capital on reverse merger transactions involving private Chinese firms that are seeking to access the U.S. capital markets.
The balance of the trip has been spent visiting prospective Redwood Capital clients in various locations, including Shanghai, and there will be multiple working meetings with Shandong Green Paper.
"Virtually every aspect of this trip, from reviewing SINO UJE's presence at the China International Medical Equipment Fair to these meetings with current and prospective Redwood Capital clients, are directly related to the expansion strategy for our subsidiaries operating in China and the efforts to deliver value for S3 shareholders," stated Mr. Bickel before leaving Dalian for Hong Kong. "Revenue expansion continues to be our primary focus.
"We look forward to our activities on the remainder of this trip and reporting our progress, including the potential of new clients for Redwood Capital, once our visit to China is concluded," he added.
To sign up to receive information by email directly from S3 Investment Company when new press releases, investor newsletters, SEC filings or other information is disclosed, please visit http://www.s3investments.com/investors/.
About S3 Investment Company
S3 Investment Company, Inc. (http://www.s3investments.com) is a holding company with two subsidiaries doing business in the China market. S3 holds a 100% equity interest in Redwood Capital (http://www.redwoodcapinc.com), which assists private Chinese companies in accessing U.S. capital markets by utilizing a network of investment banking relationships, and a 51% equity interest in SINO UJE (http://www.sinouje.com), a non-stocking distributor of medical and industrial high-tech products to markets throughout China. SINO UJE has been granted exclusive distribution rights in China to medical and industrial products manufactured by leading companies in Europe, North America and Japan. These products are marketed to end-users, including major Chinese hospitals and private companies in a variety of fields, as well as original equipment manufacturers (OEMs), such as Phillips, Siemens and GE, that package the products with their technologies.
Any statements contained herein related to future events are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on forward-looking statements. S3 Investment Company, Inc. undertakes no obligation to update any such statements to reflect actual events.
Contact:
Contact:
Gemini Financial Communications for S3 Investment Company
A. Beyer
(951) 587-8072
Email Contact
--------------------------------------------------------------------------------
But yes I would agree that you and some of the others have contributed to the price decline. The market makers take advantage of the negative sentiment on the board to create an even more negative attitude by driving the price down. Why do you think flaffy comes around so often. He probably works for one of the market makers. And you are his tool. Nice. lol
I always notice that as soon as the price drops you blow up like Mt. Vesuvias LOL. I knew when someone dropped the price this morning that you would be posting shortly thereafter. Thanks for the laugh.
I was all for the reverse split. So Im not the one complaining about it.
Nicely done Dan. Thank the company on my behalf. All investors want is a little communication. (Although greater share price appreciation would be nice also lol) Thanks.
I bought in yesterday and liquidated some other stocks including a few oilers. They have begun drilling on the second well in Niger, the Fachi West 1. Its worth a gamble at this price.
LOL I enjoyed the banter. Thanks for the entertainment.
But I understand, you were just doing your job Flaffy....
Which marketmaker are you employed by again?
BTW my average cost here is .08. How about you flaffy?
It looks like you were wrong about Cintel. You were bashing it when the stock was trading at .06. Now its at .40. Have you apologized to the board yet?
Thanks for the link flaffy.
Why was everyone so hostile towrads lowman?
I can tell you that I complained to Investor Relations about the fact that I would have liked them to PR the Redwood signings that were mentioned in the video. And guess what happened. They did PR a Redwood signing. So in my opinion they did take a step to respond to a suggestion. If they dont PR them then everyone complains that they are not keeping us abreast of things. And if they do PR them then they are accused of pumping because the reverse merger hasnt actually been completed yet. So in a sense they are _______ if they do and ______ if they dont.
At least they made the effort to listen to a suggestion. I believe they are making an honest effort to get the word out on the company. We are paying for slow approval times in China ie Abaxis, and the gap in Redwood signings which have occurred. I believe those issues will be resolved and the company is on the right path. When will they be resolved I dont know. But when those issues are resolved earnings will improve and the share price will improve.
Regardless the market cap is far below what it should be based on current sales and FSIN holdings imo.
Really then why do you continue to post here?
Myth I have criticized this company management publically on many occasions. I also feel the actual busineses will do well. Its called giving a balanced account of what is going on. I actually feel this is one of the most undervalued stocks on the market. But I am not enthralled with management. So it is a mixed situation.
Actually I have posted both positive and negative posts about the company. So I dont really understand what you are trying to imply.
I dont quite understand the price action on HMGP. They announce a very successful well and the price drops. Investors and traders alike must understand that oil stocks should be treated differently then other stocks when it comes to trading. The value of the underlying assets were increased yesterday with the announcement of the well. Sell the news should not apply here. This is a buy and hold. With every well that is hit the underlying value of the asset and thus the stock should increase. Oil stocks should be played differently then other stocks. It seems as if with the constant emphasis on charting techniques that we have created a bunch of robots who dont know or understand how to look at the actual fundamentals of the company iteslf.
Cintel appears to be getting its act together. Nice run lately.
I would say $15 to $20 is reasonable.
Let me tell you something. I blame 40% of the share price woes on the Bickels and about 60% on the negative sentiment of the posters here. No one here ever discusses the business itself. The market in China, etc etc, Its nothing but whining and crying about the share price. Many of you have gotten what you deserve. This board is so overridingly negative that no one would ever read this board and buy the stock. If I was moderator the majority of the posts here would have been deleted. S3 has some good things going for it but you would never know it by reading the board.
P.S. I have the perfect stock for many of you.
G-E-R-B-E-R-S
I have never seen a bigger bunch of whiny babies in all of my life.
GLTY to you morons. You will need it. I wont be posting here any longer. Its a waste of time.
Read post #4102 and learn something.
But I am not as heavily invested here as some others so maybe that is why I am not as hostile.
That's your opinion. I have a different opinion. GLTY
See post 4102 for my response.
Why, because I was hoping that they would announce a follow-up PR about getting SFDA approval at the conference. I also posted about this stock because I feel it is woefully undervalued at these levels. I am actually trying to get the word out on the stock so that other investors might take a look at it. Maybe if more posters here would do that instead of spending all day here whining about the share price to each other the share price would be higher. The fact of the matter is that the FSIN shares that SIVC holds is worth $1 million to SIVC and yet the stock is trading at a market cap well under $1 million. The stock should be much higher. I feel it is a bargain at these levels so I actually took the time to try and inform others about the stock. Maybe if some of you would get off your azzes and do the same we would get more buying interest.
Like someone had posted earlier. Pink sheets stocks trade largely on word of mouth on message boards. If you and others are waiting for Joe Kernen to mention it on CNBC then you will have a long wait. This company has much more going for it then many of the other pink stocks which have gone on big runs. That is why I mentioned it.
Nice well today. Congrats to Hemi management.
You don't find it a little odd that E-CHENG MEDICAL SYSTEMS LDT lists Sino Uje as their warranty contact ? (Uh No) Or that their co profile is almost word for word as that of Sino's ? (Uh No) Or that Sino Uje LTD was not listed on the CMEF list of exibitors ? (No) Or that Abaxis has not made ANY public statements concening their big unveiling at the show ? (No)
Myth, as you know, this company and management will ultimately be judged on share price. That is really the only thing that matters. And obviously the share price is pathetic. So they get a failing grade thus far and that is putting it mildly.
Myth, I dont think saying that you are going to exhibit at a conference is going to move the share price. If they had released a PR saying that the Abaxis product line had obtained SFDA approved then that might move the stock. Saying that you are going to have a booth at a medical conference is not exactly exciting news.
I dont know. But the market maker GLBT is and has been sitting on the ask at .017 for the last several days. GLBT is GLB Trading, Inc. from Irvine, California.
But its hard to tell what is going on because there has not been enough buying pressure to determine whether the stock would move up readily or not. Yes I know 700,000 shares were traded in one day last week. But that is only $9000 worth of a stock.
I dont know, but if the company says in a PR that they plan on converting the preferred shares to common shares immediately then they should have issued a follow-up PR to explain why they haven't been converted if indeed they haven't.
This company has two businesses that will eventually do very well imho. That being Sino and Redwood. That is the positive. The negative of this company is the way management has, thus far, handled the PR's, the share structure, and the share price. Lets hope they turn things around and are more forthcoming going forward.
I really dont understand the point of the majority of the posts today. Did you people think that Sino is the only medical supplier doing business in China? Of course there are other medical wholesalers who do business in China. Its a large country and its called competition. Last time I checked no one was claiming that Sino had a monopoly in the Chinese market.
S3 has said they will be the "exclusive" supplier of Abaxis in China anyway.
I bought some this week. I liquidated some other holdings to buy this. It might take some time but eventually it will ramp up from here.
I bought more also. Sold several other stocks to jump in.
RGNO is about due for some news. It is one to keep an eye on imo.
FSIN closed up yet again at $10.99. If there is another stock more undervalued than SIVC I would like to see it.
S3 Investment Company Announces SINO UJE Exhibit at China International Medical Equipment Fair
Issued Tuesday April 10, 9:02 am ET
DANVILLE, CA--(MARKET WIRE)--Apr. 10, 2007--S3 Investment Company, Inc. (Other OTC: SIVC), a holding company with two subsidiaries doing business in the China market, has announced that its SINO UJE subsidiary will begin exhibiting today at the China International Medical Equipment Fair Spring 2007 Conference in Dalian, China. The event runs from today to Friday, April 13, 2007 at the Dalian World Expo Center in Dalian Xinghai Square.
According to event organizers, the conference enjoys strong support among its key customers including GE, Johnson & Johnson, Kodak, Siemens, Roche, Hitachi, Toshiba, Aloka, Sony, Olympus, Zeiss, Erbe, Datex-Ohmeda, Pentax, Samsung, Fuji, Shimadzu, Agfa, and Drager, as well as leading Chinese manufacturers like Wandong Medical, Neusoft and Mindray.
A major focus of SINO UJE’s exhibit at the conference will be the introduction of the product line of new supplier Abaxis, Inc., a publicly traded company that develops, manufactures and markets portable blood analysis systems for use in patient-care setting to provide clinicians with rapid blood constituent measurements.
China International Medical Equipment Fair organizers state that the Chinese market for medical equipment and supplies was estimated at $2.6 billion (USD) in 2005. This market continues to boom, with continued investment from overseas along with substantial domestic production. Imports have grown rapidly in recent years, passing the $2 billion mark in 2003, dominated by expensive high-end products. A large and aging population, an increasing standard of living and expectations of continuing healthcare standards, together with the current low penetration of domestic medical devices, combine to make China a huge and attractive import market. Chinese government initiatives aimed at creating a better operating environment are making China more conducive to overseas suppliers.
“We continue to be extremely excited about the potential of the Abaxis product line in China, and as exclusive distributor into this enormous market, SINO UJE is planning carefully for the successful introduction and marketing launch for Abaxis in China,” commented Jim Bickel, chief executive officer of S3 Investment Company. “This conference is expected to play an important role in the introduction of Abaxis to the medical industry in China, and we look forward to SINO UJE’s exhibit as a key part of this introduction.
“We expect the Abaxis product line to be an excellent revenue producer for our SINO UJE subsidiary and contribute to an improving bottom line for S3,” added Mr. Bickel
Public Reply | Private Reply | Keep | Last Read Next 10 | Previous | Next
S3 Investment Company Announces SINO UJE Exhibit at China International Medical Equipment Fair
Issued Tuesday April 10, 9:02 am ET
DANVILLE, CA--(MARKET WIRE)--Apr. 10, 2007--S3 Investment Company, Inc. (Other OTC: SIVC), a holding company with two subsidiaries doing business in the China market, has announced that its SINO UJE subsidiary will begin exhibiting today at the China International Medical Equipment Fair Spring 2007 Conference in Dalian, China. The event runs from today to Friday, April 13, 2007 at the Dalian World Expo Center in Dalian Xinghai Square.
According to event organizers, the conference enjoys strong support among its key customers including GE, Johnson & Johnson, Kodak, Siemens, Roche, Hitachi, Toshiba, Aloka, Sony, Olympus, Zeiss, Erbe, Datex-Ohmeda, Pentax, Samsung, Fuji, Shimadzu, Agfa, and Drager, as well as leading Chinese manufacturers like Wandong Medical, Neusoft and Mindray.
A major focus of SINO UJE’s exhibit at the conference will be the introduction of the product line of new supplier Abaxis, Inc., a publicly traded company that develops, manufactures and markets portable blood analysis systems for use in patient-care setting to provide clinicians with rapid blood constituent measurements.
China International Medical Equipment Fair organizers state that the Chinese market for medical equipment and supplies was estimated at $2.6 billion (USD) in 2005. This market continues to boom, with continued investment from overseas along with substantial domestic production. Imports have grown rapidly in recent years, passing the $2 billion mark in 2003, dominated by expensive high-end products. A large and aging population, an increasing standard of living and expectations of continuing healthcare standards, together with the current low penetration of domestic medical devices, combine to make China a huge and attractive import market. Chinese government initiatives aimed at creating a better operating environment are making China more conducive to overseas suppliers.
“We continue to be extremely excited about the potential of the Abaxis product line in China, and as exclusive distributor into this enormous market, SINO UJE is planning carefully for the successful introduction and marketing launch for Abaxis in China,” commented Jim Bickel, chief executive officer of S3 Investment Company. “This conference is expected to play an important role in the introduction of Abaxis to the medical industry in China, and we look forward to SINO UJE’s exhibit as a key part of this introduction.
“We expect the Abaxis product line to be an excellent revenue producer for our SINO UJE subsidiary and contribute to an improving bottom line for S3,” added Mr. Bickel
Public Reply | Private Reply | Keep | Last Read Next 10 | Previous | Next